Detalhe da pesquisa
1.
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).
Int J Mol Sci
; 24(13)2023 Jun 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37445722
2.
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
J Transl Med
; 19(1): 184, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33933113
3.
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.
J Transl Med
; 18(1): 99, 2020 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32087721
4.
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Breast Cancer Res
; 19(1): 87, 2017 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28750640
5.
The prevalence of hypertension in paediatric Turner syndrome: a systematic review and meta-analysis.
J Hum Hypertens
; 37(8): 675-688, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36471031
6.
Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer.
Cancer Biol Ther
; 24(1): 2223388, 2023 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37326340
7.
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER".
Cancers (Basel)
; 13(6)2021 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33799597
8.
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer.
Obstet Gynecol Sci
; 63(5): 643-654, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32872764
9.
Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.
Cancers (Basel)
; 12(7)2020 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32640573
10.
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
PLoS One
; 13(8): e0200996, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30071039
11.
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.
Ther Adv Med Oncol
; 10: 1758834017746040, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29383036
12.
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.
Ther Adv Med Oncol
; 10: 1758835918778297, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30023006
13.
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
Oncotarget
; 8(49): 85120-85135, 2017 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29156708
14.
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
Oncotarget
; 7(46): 75518-75525, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27776352